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Synthetic grafts used for arterial bypass or inter-
position have better rates of patency when lined with
autologous endothelium compared with unlined
control grafts.1 In more recent studies, grafts seeded
with genetically modified endothelial cells have had
decreased cell adherence when compared with grafts
seeded with unmodified cells, introducing a new
variable into the evaluation of graft patency. Tissue
culture and in vitro studies in our laboratory indi-
cated that changes in the techniques used for graft
preparation and seeding may improve endothelial
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cell adherence.2 The purpose of this study was to
determine whether in vivo adherence of genetically
modified endothelial cells could be improved and
graft patency affected by the methodologic changes
suggested by these acute studies. Specifically
addressed were the method of graft lumen coating
with fibronectin, the process of cell selection after
transduction, and the time of incubation of cell-
lined grafts before exposure to in vivo blood flow
conditions.
MATERIALS AND METHODS
Conditioned adult mongrel dogs, each weighing
20 to 25 kg, were maintained for at least 5 days
before surgery in an animal care facility approved by
the American Association for the Accreditation of
Laboratory Animal Care. The study was approved
by the Institutional Review Board of William Beau-
mont Hospital and all animal care complied with the
Guide for the Care and Use of Laboratory Animals.3
Every animal was evaluated before operation for
platelet aggregation in vitro using a whole blood
lumiaggregometer (Chrono-log, Havertown, Pa.)
with arachidonic acid stimulation.4 Only nonaggre-
gators, defined as less than 20% aggregation, were
used in the study. Surgical procedures were carried
out using sterile technique with the dog under gen-
eral anesthesia with isoflurane, 1.5% to 2%. Animals
were intubated and ventilated with room air using a
constant volume ventilator at a tidal volume of 15
ml/kg and a rate of 10 to 13 breaths per minute.
Intravenous lactated Ringer’s solution was infused at
a rate of approximately 5 ml/kg/hr.
Endothelial cell harvest. Endothelial cells were
harvested from the external jugular veins of each
animal. Ten-centimeter lengths of both external
jugular veins were excised through longitudinal neck
incisions. The vein was handled minimally through-
out the dissection, and a topical papaverine (Eli Lilly,
Indianapolis) bathing solution, 0.1 mg/ml, was
used to prevent vasoconstriction.5 Side branches
were ligated and divided at least 2 mm from the
jugular vein. Cells were harvested by an enzymatic
single-stage technique.6 The vein was everted on a
16-gauge catheter, placed briefly in culture medium
M199 (Whittaker Bioproducts, Walkersville, Md.),
and then immersed in 0.2% type II collagenase
(Worthington, Freehold, N.J.) in phosphate-
buffered saline solution (PBS) for 20 minutes. The
solution was centrifuged at low speed, and the pel-
leted cells were resuspended in endothelial cell
growth medium of M199 supplemented with 20%
calf serum with iron (Hyclone, Logan, Utah), 3
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m g/ml endothelial cell growth supplement (Collab-
orative Research, Bedford, Mass.), 90 m g/ml
heparin, 0.1% insulin-transferrin-selenium mix (Col-
laborative Research), and 1% each of L-glutamine,
sodium pyruvate, nonessential amino acid mix
(Gibco, Grand Island, N.Y.), and antibiotic mix
(Whittaker Bioproducts). The yield from each
length of vein was approximately 2.5 · 105 cells.
Endothelial cell transduction. Harvested cells
were cultured in gelatin coated T-75 flasks (Becton
Dickinson, Franklin Lakes, N.J.), with 80% of the
cells from the original harvest placed in one flask for
later transduction and the other 20% into a separate
flask to serve as a nontransduced cell culture. Trans-
duction was begun the following day when the flask
for transduced cells had reached 30% to 40% conflu-
ence; nontransduced cells were allowed to grow to
approximately 5 · 106 cells and then split using
trypsin. Purity of cultures was confirmed by
immunostaining for factor VIII–related antigen and
smooth muscle actin by means of the labeled avidin-
biotin method using streptavidin peroxidase.
Transduction was done by incubation of cells
with 104 to 106 CFU/ml of an LXSN-type retrovi-
ral vector carrying a gene for human prourokinase
and a neomycin resistance gene for selection in
antibiotic G418,7,8 with the virus mixed 1:1 with
culture medium containing 8 m g/ml of polycation
Polybrene (Sigma, St. Louis, Mo.). The recombi-
nant LXSN-type retroviral vector contains the long
terminal repeat (LTR) of the Moloney murine
leukemia virus and the SV 40 promoter, and it has
been successfully transfected into canine endothelial
cells.7-9 Cells were exposed to the retroviral vector in
the presence of Polybrene for two 8-hour exposures
at 32° C on successive days, with the cells incubated
at 37° C in culture medium during the recovery
period between exposures; transduction efficiency
using this technique was approximately 1% to 15%.10
Successfully transduced cells were selected by incu-
bation in media with 400 m g/ml G418 for 14 days.
Urokinase assays. Cells that produced urokinase
were identified by immunohistochemical staining
with monoclonal antibody recognizing human uroki-
nase (uPA B-chain, American Diagnostica, Green-
wich, Conn.). The staining protocol was 10% neutral
buffered formalin for 20 minutes, PBS rinse, 3%
H2O2 for 5 minutes, 10% goat serum blocker for 20
minutes, primary antibody for 30 minutes, PBS rinse,
secondary antibody (goat antimouse biotin conjugate
1:800, Sigma, St. Louis), PBS rinse, ExtrAvidin per-
oxidase (Sigma) for 20 minutes, and visualization of
avidin-biotin complex with 3-amino-9-ethylcar-
bazole. Quantitation of urokinase in culture medium
from the transduced cells was determined immuno-
chemically with a commercial enzyme-linked immu-
nosorbent assay kit (American Diagnostica, Green-
wich, Conn.). Aliquots of culture medium and stan-
dards were incubated overnight in microtest wells
coated with mouse antihuman urokinase monoclonal
antibody. Wells were then incubated sequentially with
biotinylated secondary antibody, streptavidin-peroxi-
dase conjugate, and the chromogen derivatized
tetramethylbenzidine. Absorbances were measured at
450 nm. Enzyme activity of urokinase in cells or cul-
ture fluid was determined by an indirect spectropho-
tometric assay based on plasminogen activation, a
minor modification of the technique of Mira-Y-
Lopez.11 Ten-microliter aliquots of culture medium
or cell lysate in 96-well plates were incubated with 2
m g human plasminogen in 115 m l of 0.1 mmol/L
Tris, pH 8.1, with 0.1% Triton X-100, for 2 hours at
37° C. The plasmin formed was quantitated by
adding 15 m l of 1 mg/ml Spectrozyme-PL (American
Diagnostica), and absorbance at 405 nm followed.
Dilutions of human uPA standard (Sigma) containing
0.04 to 20 Plough mU/well were included in the
assay as control specimens.
Graft preparation. All grafts were 4 mm inner
diameter expanded polytetrafluoroethylene (ePTFE;
W.L. Gore and Associates, Flagstaff, Ariz.) with an
internodal distance of 22 m m. As described in detail
below, control grafts had passive luminal coating
with fibronectin and were seeded with transduced
endothelial cells immediately after G418 selection;
these grafts were incubated for 2 days before implan-
tation. Experimental grafts had fibronectin forceful-
ly squeezed through the interstices and were seeded
with endothelial cells that had recovered in culture
for 5 days after G418 selection; these grafts were
incubated for 4 days before implantation. Ten-cen-
timeter lengths of control graft had the luminal sur-
face passively coated with fibronectin (Boehringer-
Mannheim, Indianapolis) using a modification of
the technique of Kesler et al.12 Grafts were filled
with fibronectin solution, 0.1 mg/ml in PBS, which
was held inside by heat-crimping the ends of the
graft. Sterile “O” rings were placed on the outside of
each end of the graft, which was then placed in a
sterile test tube in a roller drum apparatus at 37° C
and rotated at 0.25 rpm for 1 hour.
Experimental grafts were pretreated by first fill-
ing the graft with fibronectin solution, clamping the
ends of the graft, and then manually squeezing the
fibronectin through the interstices of the graft to
assure coverage of the interstices and uniform bridg-
ing between the graft surface ridges.2 After empty-
ing the graft lumen of any remaining solution, a sec-
ond coating of fibronectin was applied using the
same technique described above for the control
grafts.
After 1 hour of rotation, excess fibronectin solu-
tion was removed from all grafts, and they were
refilled with a suspension containing 1.91 (±0.29) ·
106 endothelial cells. The graft ends were reclosed
and the grafts placed back in the roller drum appa-
ratus for 2 hours, when they were removed and the
cell suspension drained from the lumen for counting
of cells not retained. Retention of transduced cells
for both control and experimental grafts was 94% ±
6%; retention of nontransduced cells was 96% ± 2%.
Endothelial cell seeding. Endothelial cells
were seeded onto control grafts immediately after
selection of successfully transduced cells by incuba-
tion in G418. For experimental grafts, successfully
transduced cells were recovered in culture using
endothelial cell growth media for 5 days before graft
seeding. For each of the control and experimental
grafts seeded with transduced cells, a corresponding
control and experimental graft was prepared and
seeded simultaneously with nontransduced cells
from the same animal, using the techniques
described above. All seeded grafts were then placed
in a 100 mm culture dish that contained endothelial
cell growth media and were incubated at 37° C and
5% CO2 and turned once daily. Control grafts were
kept under these conditions for 2 days before
implantation; experimental grafts were incubated for
4 days before implantation.
Graft implantation and explantation. For
each animal a set of either control grafts (n = 9) or
experimental grafts (n = 12), one with transduced
cells and one with nontransduced cells, was implant-
ed (Table I). Using general anesthesia and sterile
technique, both carotid arteries were exposed
through a midline incision in the neck. After sys-
temic anticoagulation using intravenous sodium
heparin, 100 U/kg, a 5 cm segment of each carotid
artery was resected and replaced with a 6 cm seg-
ment of seeded ePTFE using 7-0 polypropylene
suture for the anastomoses. The graft that contained
transduced cells was randomly assigned to the right
or left side, and the surgeon was not aware of which
graft had been seeded with transduced cells. After
closure of the incision the animals were housed in
individual cages and allowed food ad libitum.
All grafts remained in place for 30 days. The ani-
mals were returned to the operating room and anes-
thetized and ventilated as before. The grafts were
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exposed by reopening the previous midline incision,
and patency was determined by transecting the
carotid artery 3 cm beyond the distal anastomosis
and evaluating for blood flow. If there was no flow
the graft was classified as occluded. The grafts were
then excised and flushed with M199 if patent. The
anastomoses were removed and placed in formalin
fixative. The grafts were opened longitudinally, and
their gross appearance was recorded and pho-
tographed.
Graft analysis. To document the presence of
transduced cells, immunohistochemical staining of
cross-sectional slices was performed as described ear-
lier for light microscopic identification of cells that
produced human urokinase. In addition, randomly
selected small clear areas of patent graft lumens, for
both transduced and nontransduced cell seeded
specimens, were lightly scraped to remove any cells
present. These cells were grown to confluence in
culture wells and then harvested and pelleted by
centrifugation. The pellets were lysed, and poly-
merase chain reaction amplification of DNA was per-
formed using primers upstream and downstream of
the urokinase gene in the retroviral construct.
Agarose gel electrophoresis was used to demonstrate
the presence or absence of a visible band corre-
sponding to the amplification product and com-
pared with a positive urokinase control plasmid.
After removal of graft samples for cell scraping,
the remaining graft material was immersed in 2.5%
glutaraldehyde-buffered solution for subsequent
analysis and histologic studies of surface healing
characteristics by scanning electron and light
microscopy. Gross surface characteristics of each
patent graft were first evaluated by computerized
image analysis. A high-resolution video image of the
graft surface was digitized, and image characteristics
identified as being indicative of surface thrombus,
fibrin/platelet layering, and clear surface areas were
assigned gray scale levels. Image analysis was then
used to calculate the percent of graft surface area
corresponding to each parameter and to determine
the percentage of thrombus-free surface area
(TFSA). The procedure was blinded between opera-
tors, and the average of five repeated, nonsequential
analyses of each graft surface used to provide an esti-
mate of parameters free from operator bias.
Samples for microscopy were taken from all
patent grafts from several standardized points
throughout the interior of the graft. Light
microscopy samples were removed from the primary
fixative, embedded in B4 resin (Pallescences, War-
rington, Pa.), and sectioned at 6 m m thickness. Each
specimen was oriented in the block so that sections
were cut perpendicular to the surface of the graft.
Sections were stained with hematoxylin and eosin,
and endothelial cell profiles were evaluated and
expressed as a percent confluence; percent cell-free
surface area (CFSA) was calculated as the comple-
ment of confluence, that is, CFSA = 100% – % con-
fluence. Samples for scanning electron microscopy
were observed with and without freeze fracture
technique and were evaluated for the surface charac-
teristics of the graft, the distribution of cells, and
patterns of cell growth.
RESULTS
By enzyme-linked immunosorbent assay, all mea-
surements of specimens from nontransduced cells
showed zero levels of human urokinase. Measure-
ments of human urokinase in culture medium from
transduced cells made before graft seeding were
43.7 ± 33.8 ng/day/106 cells for control graft sam-
ples and 124.5 ± 86.8 ng/day/106 cells for experi-
mental graft samples (p = 0.016). After graft seeding
and just before implantation human urokinase levels
were 43.0 ± 46.1 ng/day/106 cells for control grafts
and 55.1 ± 41.1 ng/day/106 cells for experimental
grafts (p = 0.522).
Immunohistochemical staining of explanted
graft sections was positive for active urokinase pro-
duction for transduced cells and negative for non-
Table I. Preparation of grafts before implantation.
Control grafts Experimental grafts
Transduced cells Nontransduced cells Transduced cells Nontransduced cells
Endothelial cell Seed immediately Standard culture Recover 5 days after G418 Standard culture 
preparation after G418 selection and incubation selection before seeding and incubation
Graft preparation Passive fibronectin Passive fibronectin “Squeeze-through” “Squeeze-through” 
coating coating fibronectin coating fibronectin coating
Incubation of Incubate 2 days Incubate 2 days Incubate 4 days Incubate 4 days
grafts after seeding
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transduced cells for both control and experimental
grafts (Fig. 1). In addition, a visible band corre-
sponding to the urokinase control plasmid band was
present on agarose gel electrophoresis of the poly-
merase chain reaction amplification product from
transduced cell specimens; this band was absent on
specimens derived from nontransduced cells.
Thirty days after implantation, no significant dif-
ferences in patency rates were seen for any of the
grafts (Table II). Control grafts were patent bilater-
ally in five animals and occluded bilaterally in two
animals; in the remaining two animals only one graft
was patent, one each with transduced and nontrans-
duced cells. The overall patency rate for control
grafts was thus six of nine (67%) for transduced cells
and six of nine (67%) for nontransduced cells. For
experimental grafts, seven animals had bilaterally
patent grafts, with no bilaterally occluded grafts.
One of the remaining five animals had a single
patent graft with transduced cells and four had sin-
gle patent grafts of nontransduced cells, for an over-
all patency rate of eight of 12 (67%) for transduced
cells and 11 of 12 (92%) for nontransduced cells 
(p = 0.158).
TFSA was also similar for all graft types. For con-
trol grafts, the TFSA was 94% ± 4% and 76% ± 14%
for nontransduced and transduced cells, respectively.
For experimental grafts the TFSA was 94% ± 9% and
90% ± 16% for nontransduced and transduced cells,
respectively. Although the TFSA was higher for
experimental grafts than for control grafts when
seeded with transduced cells, this difference did not
achieve significance (p = 0.115).
Adherence of transduced cells was significantly
greater for experimental grafts than for control
grafts. Based on light microscopy data, CFSA (a
measure of cell loss) on experimental grafts seeded
with transduced cells was 65% ± 28% compared with
96% ± 5% for control grafts (p = 0.021). Retention
of transduced cells on experimental grafts was com-
parable with that for nontransduced cells on both
experimental grafts (CFSA, 51% ± 19%; p = 0.201)
and control grafts (62% ± 22%; p = 0.830). Data
obtained from scanning electron microscopic evalu-
ation of patent graft luminal surfaces show even fur-
ther decreases in cell-free areas compared with light
microscopic data. The mean CFSA for control grafts
was 44.5% ± 32.8% and 80.8% ± 23.3% for non-
transduced and transduced cells, respectively. For
experimental grafts the CFSA were 19.6% ± 24.5%
and 45.4% ± 39.2% for nontransduced and trans-
duced cells. For all grafts, scanning electron
microscopy generally indicated better endothelial
cell coverage and showed lower percentages of
CFSA than did light microscopy.
DISCUSSION
The long-range goal of endothelial seeding has
been to develop a biologically active lining for syn-
thetic grafts that will decrease luminal thrombo-
genicity and promote long-term patency of these
grafts. It has been shown by previous investigators
that endothelial cells could be genetically altered
before being seeded onto synthetic vascular grafts.13
This study has focused on endothelial cell adherence
when using autologous cells to cover the surface of
grafts before implantation compared with those
grafts in which autologous endothelial cells have
been genetically modified to produce human uroki-
nase before graft seeding.
Earlier studies by other investigators showed
minimal success obtaining in vivo adherence of
genetically modified endothelial cells to synthetic
grafts, significantly limiting the potential of these
techniques to clinical application. Dunn et al.14
found only 6% median retention of endothelial cells
that had undergone LXSN retroviral transfection
with a gene for tissue plasminigen activator, using 
4 mm inner diameter Dacron grafts exposed to 
2 hours of flow in an in vivo model in sheep. Similar
to our canine model, 12 of the 40 grafts studied
were placed in the carotid position, and these grafts
showed only 9% retention of endothelial cells. They
found only increasing cell passage level to be mod-
estly inversely correlated with cell adherence, with
no significant effects noted for graft length or length
of flow time in vivo.
Fig. 1. Immunohistochemical stain for human urokinase
on an experimental graft specimen seeded with transduced
cells and explanted at 30 days (original magnification, 40· ).
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In a study by Sackman et al.15 endothelial cells
were transduced in vitro using a retroviral LXSN
vector and then seeded onto PTFE grafts before
placement as extraanatomic aortic bypass grafts in a
canine model. Only one of the three animals studied
had histologic evidence of endothelial cells on the
graft at explantation after 3 weeks; and by scanning
electron microscopy the one animal with cells pre-
sent had approximately 50% surface coverage. They
concluded that the uniformly poor graft endothelial-
ization by transduced cells that they observed in vivo
was not significantly altered by the initial cell-seed-
ing density, the graft surface substrate, the type of
retroviral vector, or cell adherence time.
Baer et al.16 implanted 10 mm inner diameter
ePTFE grafts in the thoracoabdominal aortic posi-
tion in seven dogs. These grafts were seeded with
autologous retroviral-mediated transduced endothe-
lial cells carrying the lac Z gene and were explanted
at 6 weeks for analysis. Three grafts seeded with
early passage transduced cells had 28% cell conflu-
ence, with 14% of endothelial cells expressing lac Z.
Four grafts seeded with late-passage transduced cells
had 42% of the graft lumen covered by endothelial
cells at explantation, but only 5% of cells expressed
lac Z. Although there was greater endothelial cell
coverage corresponding to a higher level of passage,
fewer cells produced the lac Z gene, similar to the
findings of Dunn et al.,14 and they concluded that
cell transduction adversely affected adherence on
grafts in vivo.
This study has investigated several methodologic
changes to attempt to improve adherence of geneti-
cally modified endothelial cells. In evaluating cell-
seeding techniques, previous studies in our laborato-
ry showed that if transduced cells were allowed to
recover in culture for 5 days after selection by G418,
confluence of seeded grafts rapidly reached 100%. If
cells were used to seed grafts immediately after
G418 selection, confluence reached only 60% over
the same time period. In addition, our previous pro-
tocols provided for an incubation time of only 2 days
between graft seeding and implantation. After 2
days, however, microscopic evaluation of the graft
surface showed that the endothelial cells present did
not appear to be healthy; they had an uneven distri-
bution with curled cytoplastic edges at cell junc-
tions, and they exhibited poor hematoxylin staining.
After 4 days of incubation at 37° C in 5% CO2, the
morphologic appearance of the cells was markedly
improved, showing a more even distribution, typical
cobblestone morphologic features with good defini-
tion of cellular junctions, and clear nuclear detail
with hematoxylin staining.
Finally, we modified the technique of coating the
graft lumen with fibronectin before cell seeding. The
fibronectin was first forcefully squeezed through the
graft interstices before a second coating was done in
the conventional “passive” manner. A comparison of
grafts treated in this fashion with grafts passively coat-
ed only showed highly significant improvement in cell
adherence after 2 hours of in vitro pulsatile perfusion
at physiologic shear rates up to 13.1 dyne/cm2.2
In the present report, we compared endothelial
cell adherence and patency data for grafts interposed in
the canine carotid position after 30 days of implanta-
tion. Autologous and genetically modified autologous
endothelial cells were seeded onto these grafts before
implantation, which were prepared and handled using
different methods. These changes in technique result-
ed in a significant improvement in adherence of genet-
ically modified endothelial cells compared with control
grafts prepared using earlier, conventional techniques
as well as with data reported in the literature. Patency
was evaluated at only one time interval, 30 days after
implantation, and further study is needed to deter-
mine whether it is significantly influenced by genetic
modification of the endothelium.
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Dr. Allan D. Callow (Boston, Mass.). This field
becomes increasingly complicated as we get into more and
more molecular biology. I am not sure from your paper that
I am fully aware of what you intend to do. If, for example,
you can improve thrombus-free surface with genetic modi-
fication of endothelial cell and you can also improve it with
better coverage by squeezing some fibrinectin in there, why
bother with the genetic modification? I am told genetic
modification of cells is a very traumatic experience. G418 is
a toxic substance that kills cells, and, as you have nicely
demonstrated, if you allow these cells to recover from the
beating that they receive, they do a bit better. If you do a
number of studies on them, such as prostacyclin produc-
tion, then the benefits that endothelial cells are supposed to
have are depressed. If you put an endothelial cell on a fab-
ric to which it is not accustomed where there is no extracel-
lular matrix, there may be good or harm. I think it is bene-
ficial; it too does not behave properly. 
I have several questions. First, what is the contribution
of the prourokinase that you put in there? I am not sure
that you identified it by the immunochemical staining, but
you did not measure it as far as I could tell. I think that
the measurement in the paper for which you give us the
nanograms is from the supernatant, and it does collect.
Another point is that, irrespective of whatever method
we use for transduction, it is not permanent, and produc-
tion gene expression falls rapidly after about the second or
third week. In some cases, they persist longer than that,
for example, the adenovirals, viruses last longer. However,
we do not know how much urokinase was in there, and if
you are trying to lessen the effect of thrombin, for exam-
ple, by the presence of urokinase, and thereby diminish
the amount of thrombus-free surface, it would be impor-
tant to know if these cells are truly producing urokinase
for more than just a short period of time.
Maybe you can also tell us if one of the problems of
endothelial cell seeding is the destructive effect of actually
suturing the end of the graft to the host artery. Whatever
method one uses to secure adherence of the cell, the very
manipulation with forceps and sutures and so forth does
destroy that, which is the area where you want the most
effect and reendothelialization because that is where the
restenosis begins.
Finally, although this is probably more theoretic than
real, human urokinase must generate an immune response
within the recipient organ, the dog. That may or may not
be of any clinical significance, but it may be of significance
to your preparation if, for example, it becomes bound to
IgG and is no longer an effect of a molecule.
I enjoyed the paper, and I hope you continue this
work. I think your work is important, and I do appreciate
the opportunity for the discussion. Thank you.
Dr. Jeffrey Falk. I would first like to comment on the
issue of urokinase that you discussed. We have shown by
our data that urokinase does help increase our thrombus-
free surface area, and both the experimental and control
grafts had good thrombus-free surface area even at 4 weeks
of explantation. We quantified our urokinase preimplant
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both before and at explantation by taking the graft and
scraping the cells from the graft of small portion before the
histologic evaluations. The grafts were fixed, then those
cells were grown in culture, and urokinase was quantified
from that culture. Not every single graft had cells that
grew, but the grafts that did actively produced urokinase.
Your second point concerned the problem of the graft
anastomosis with a small 4 mm–diameter graft and the
sewing to a very small carotid artery in the dog. The prob-
lems usually are in the grafts that were not patent. There
is intimal hyperplasia at the anastomosis site, which is a
problem. We use #7-0 polypropylene for anastomosis in a
single running one-layer anastomosis. This can be a big
problem in that there is definitely the possibility of reac-
tion with the human urokinase in the dogs. We are not
really sure of the effects of that.
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